At the 42nd annual event for investors, pharma executives and biotech innovators, the spotlight was on AI, the new GLP-1 class of weight loss drugs, non-profit hospitals and treatment for autoimmune disease.

A new rule, which is set to take effect Jan. 1 and requires PBMs to take most of their "performance fees" at the time prescriptions are filled, is adding to the woes of the independent drugstores it was partly designed to help.

Thousands of patients with autoimmune diseases rely on Humira, at a list price of $6,600 a month, and could benefit from low-cost biosimilars that could save the health care system $9 billion a year, but will PBMs follow suit?

Everyone over the age of 6 months should get the latest COVID-19 booster, a CDC panel recommended Tuesday, which legally obligates commercial insurance coverage of adult vaccines.

The CDC committee, which sets U.S. vaccination policy and helps determine insurance coverage for vaccines, will vote on the question Tuesday as it weighs the benefits of updated vaccines from Pfizer, Moderna, and Novavax.

Even though six drug companies have filed lawsuits to halt the Medicare drug negotiation program, the companies have until Oct. 2 to present data on their drugs to CMS, which will make initial price offers in February.

Patients with early Alzheimer's disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period.

In recent months ominous ads about prescription drugs have flooded the TV airwaves - and Congress is paying attention: House and Senate members have launched nine bills that take aim at pharmacy benefit managers.